Evaluation of the effectiveness of personalized complex therapy in patients with benign prostatic hyperplasia and chronic prostatitis

Abstract

PURPOSE OF THE STUDY: to evaluate the effectiveness of personalized complex treatment of patients with benign prostatic hyperplasia (BPH) in combination with chronic prostatitis using a combined physiotherapeutic effect, taking into account the individual chronobiological characteristics of patients.

MATERIALS AND METHODS: We examined 60 patients with benign prostatic hyperplasia and chronic prostatitis who were sent to the TUR of the prostate. Patients were divided into two groups (n = 30). The comparison group (CG) was treated with alpha-blockers and fluoroquinolones for 28 days. In the main group (MG) – personalized complex therapy. The effectiveness of treatment was evaluated at the time of treatment (visit 1), two weeks later (visit 2) and 4 weeks later (visit 3). The severity of lower urinary tract symptoms, prostate volume and residual urine volume, hemodynamic parameters in the gland were evaluated, and a bacterioscopic and bacteriological examination of prostate secretion was performed.

RESULTS: At the end of 4 weeks of therapy, statistically significant differences (p < 0.05) were found in the MG for all the studied parameters. In the bacteriological study of prostate secretions at visit 1 Escherichia coli prevailed in the crops. At visit 2 to the CG bacteria were detected in 11 (36.7%) crops, and in 10 (33.3%) patients in the MG. At visit 3, no microbial growth was detected in both groups based on the results of a bacteriological examination of prostate secretions. Initially, both groups had low hemodynamic parameters in the prostate. After the treatment, a more pronounced dynamics of improvement of blood flow in the gland by visit 2 was noted in the MG than in the GP. By visit 3, statistically significant differences were found in all the studied indicators (p < 0.05).

CONCLUSION: Thus, according to the results, a personalized comprehensive treatment of patients with benign prostatic hyperplasia and chronic prostatitis reduced the severity of lower urinary tract symptoms and manifestations of the inflammatory process in the prostate, improved hemodynamic parameters and increase of efficiency of antibacterial therapy, as evidenced by the results of bacteriological studies.

PURPOSE OF THE STUDY: to evaluate the effectiveness of personalized complex treatment of patients with benign prostatic hyperplasia (BPH) in combination with chronic prostatitis using a combined physiotherapeutic effect, taking into account the individual chronobiological characteristics of patients.

MATERIALS AND METHODS: We examined 60 patients with benign prostatic hyperplasia and chronic prostatitis who were sent to the TUR of the prostate. Patients were divided into two groups (n = 30). The comparison group (CG) was treated with alpha-blockers and fluoroquinolones for 28 days. In the main group (MG) – personalized complex therapy. The effectiveness of treatment was evaluated at the time of treatment (visit 1), two weeks later (visit 2) and 4 weeks later (visit 3). The severity of lower urinary tract symptoms, prostate volume and residual urine volume, hemodynamic parameters in the gland were evaluated, and a bacterioscopic and bacteriological examination of prostate secretion was performed.

RESULTS: At the end of 4 weeks of therapy, statistically significant differences (p < 0.05) were found in the MG for all the studied parameters. In the bacteriological study of prostate secretions at visit 1 Escherichia coli prevailed in the crops. At visit 2 to the CG bacteria were detected in 11 (36.7%) crops, and in 10 (33.3%) patients in the MG. At visit 3, no microbial growth was detected in both groups based on the results of a bacteriological examination of prostate secretions. Initially, both groups had low hemodynamic parameters in the prostate. After the treatment, a more pronounced dynamics of improvement of blood flow in the gland by visit 2 was noted in the MG than in the GP. By visit 3, statistically significant differences were found in all the studied indicators (p < 0.05).

CONCLUSION: Thus, according to the results, a personalized comprehensive treatment of patients with benign prostatic hyperplasia and chronic prostatitis reduced the severity of lower urinary tract symptoms and manifestations of the inflammatory process in the prostate, improved hemodynamic parameters and increase of efficiency of antibacterial therapy, as evidenced by the results of bacteriological studies.

Keywords

chronic bacterial prostatitis / benign prostatic hyperplasia / BPH / TUR of the prostatae / chronotherapy / physiotherapy with the Smart-Prost device / transrectal ultrasonography / Doppler

References

[1] Aljaev JG, Glybochko PV, Pushkar’ DJ, editors. Urologija. Rossijskie klinicheskie rekomendacii. Moscow: GEOTAR-Media, 2018. 480 p. (In Russ.)

[2] Урология. Российские клинические рекомендации / под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. М.: ГЭОТАР-Медиа, 2018. 480 с.

[3] Europian association of Uroligy [Internet]. Gravas S, Cornu JN, Gacci M, et al. Management of non-neurogenic male lower urinary tract symptoms (LUTS). EAU Guideline, 2020. [updated 01.02.2021]. Available from: https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts.

[4] Europian association of Uroligy [Internet]. Gravas S., Cornu J.N., Gacci M., et al. Management of non-neurogenic male lower urinary tract symptoms (LUTS). EAU Guideline, 2020. [дата обращения: 01.02.2021]. Доступ по ссылке: https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts.

[5] Roehrborn CG. Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History. Campbell- Walsh. Urology. 10th edition. 2012:2570–2610. DOI: 10.1016/B978-1-4160-6911-9.00091-8

[6] Roehrborn C.G. Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History // Campbell-Walsh Urology. 2012. P. 2570–2610. DOI: 10.1016/B978-1-4160-6911-9.00091-8/

[7] Gupta N, Rogers T, Holland B, et al. Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial. J Urol. 2018;200(2): 405–413. DOI: 10.1016/j.juro.2018.02.3088

[8] Gupta N., Rogers T., Holland B., et al. Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial // J Urol. 2018. Vol. 200, No. 2. P. 405–413. DOI: 10.1016/j.juro.2018.02.3088

[9] Roehrborn CG, Barkin J, Tubaro A, et al. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. BJU Int. 2014;113(4):623–635. DOI: 10.1111/bju.12500

[10] Roehrborn C.G., Barkin J., Tubaro A., et al. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT stud // BJU Int. 2014. Vol. 113, No. 4. P. 623–635. DOI: 10.1111/bju.12500

[11] Mustafaev AT, Kyzlasov PS, Dianov MP, et al. Surgical treatment of benign prostatic hyperplasia: the past and the present. Urologicheskie vedomosti. 2019;9(1):47–56. (In Russ.) DOI: 10.17816/uroved9147-56

[12] Мустафаев А.Т., Кызласов П.С., Дианов М.П., и др. Хирургическое лечение доброкачественной гиперплазии предстательной железы: прошлое и настоящее // Урологические ведомости. 2019. Т. 9, № 1. C. 47–56. DOI: 10.17816/uroved9147-56

[13] Roehrborn CG, Oyarzabal Perez I, Roos EP, et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart) compared with watchful waiting with nitiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;116(3):450–459. DOI: 10.1111/bju.13033

[14] Roehrborn C.G., Oyarzabal Perez I., Roos E.P., et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart) compared with watchful waiting with nitiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results // BJU Int. 2015. Vol. 116, No. 3. P. 450–459. DOI: 10.1111/bju.13033

[15] Kuz’menko AV, Kuz’menko VV, Gyaurgiev TA. Combination drug therapy in patients with BPH. Urologiia. 2018;(1):101–105. (In Russ.) DOI: 10.18565/urology.2018.1.101-105

[16] Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Комбинированная медикаментозная терапия пациентов с аденомой предстательной железы // Урология. 2018. № 1. C. 101–105.

[17] Nickel J. Prostatitis. CUA Guidelines. Can Urol Assoc J. 2011;5(5):306–315. DOI: 10.5489/cuaj.11211

[18] Nickel J. Prostatitis. CUA Guidelines // Can Urol Assoc J. 2011. Vol. 5, No. 5. P. 306–315. DOI: 10.5489/cuaj.11211

[19] Rees J, Abrahams M, Doble A, Cooper A; Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015;116(4):509–525. DOI: 10.1111/bju.13101

[20] Rees J., Abrahams M., Doble A., Cooper A. Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline // BJU Int. 2015. Vol. 116, No. 4. P. 509–525. DOI: 10.1111/bju.13101

[21] Kudryavcev YuV, Sivkov AV. Morphological alteration in benign prostatic hyperplasia tissue. Experimental and Clinical Urology. 2010;(1):18–22. (In Russ.)

[22] Кудрявцев Ю.В., Сивков А.В. Морфологические изменения ткани предстательной железы при доброкачественной гиперплазии // Экспериментальная и клиническая урология. 2010. № 1. C. 18–22.

[23] Bartoletti R, Cai T, Mondaini N, et al. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. J Urol. 2007;178(6):2411–2415; discussion 2415. DOI: 10.1016/j.juro.2007.08.046

[24] Bartoletti R., Cai T., Mondaini N., et al. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study // J Urol. 2007. Vol. 178, No. 6. P. 2411–2415; discussion 2415. DOI: 10.1016/j.juro.2007.08.046

[25] Huang XH, Qin B, Liang YW. LUTS in BPH patients with histological prostatitis before and after transurethral resection of the prostate. Zhonghua Nan Ke Xue. 2013;19(1):35–39. (In Chinese).

[26] Huang X.H., Qin B., Liang Y.W. LUTS in BPH patients with histological prostatitis before and after transurethral resection of the prostate // Zhonghua Nan Ke Xue. 2013. Vol. 19, No. 1. P. 35–39 (In Chinese).

[27] Krsmanovic A, Tripp D, Nickel J, et al. Psychosocial mechanisms of the pain and quality of life relationship for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Can Urol Assoc J. 2014;8(11–12):403–408. DOI: 10.5489/cuaj.2179

[28] Krsmanovic A., Tripp D., Nickel J., et al. Psychosocial mechanisms of the pain and quality of life relationship for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) // Can Urol Assoc J. 2014. Vol. 8, No. 11–12. P. 403–408. DOI: 10.5489/cuaj.2179

[29] Asgari SA, Mohammadi M. The role of intraprostatic inflammation in the acute urinary retention. Int J Prev Med. 2011;2(1):28–31.

[30] Asgari S.A., Mohammadi M. The role of intraprostatic inflammation in the acute urinary retention // Int J Prev Med. 2011. Vol. 2, No. 1. P. 28–31.

[31] Al-Shukri SK, Tkachuk VN, Gorbachev AG, et al. Urodinamicheskie issledovanija v diagnostike infravezikal’noj obstrukcii u muzhchin. Urologiia i nefrologiia. 1998;(6):27–29. (In Russ.)

[32] Аль-Шукри С.Х., Ткачук В.Н., Горбачев А.Г., и др. Уродинамические исследования в диагностике инфравезикальной обструкции у мужчин // Урология и нефрология. 1998. № 6. С. 27–29.

[33] Kuz’menko AV, Kuz’menko VV, Gyaurgiev TA. Acute respiratory infections, viruses, children, recombinant interferon alfa-2b. RMJ. 2019;27(10):46–49. (In Russ.)

[34] Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Эффективность макролидов в лечении больных урогенитальными инфекциями // РМЖ. 2019. Т. 27, № 10. С. 46–49.

[35] Nesterov SN, Hanaliev BV, Boneckij BA, et al. Infekcionno-vospalitel’nye oslozhnenija transuretral’noj rezekcii predstatel’noj zhelezy u pacientov s hronicheskim prostatitom. Bulletin of the Dagestan State Medical Academy. 2017;4(25):51–54. (In Russ.)

[36] Нестеров С.Н., Ханалиев Б.В., Бонецкий Б.А. и др. Инфекционно-воспалительные осложнения трансуретральной резекции предстательной железы у пациентов с хроническим простатитом // Вестник Дагестанской государственной медицинской академии. 2017. Т. 4, № 25. С. 51–54.

[37] Kuz’menko AV, Kuz’menko VV, Gyaurgiev TA. The efficacy of fesoterodine in patients after transurethral resection of the prostate. Urologiia. 2019;(1):52–55. (In Russ.) DOI: 10.18565/urology.2019.1.52-55

[38] Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Эффективность применения фезотеродина у больных после трансуретральной резекции предстательной железы // Урология. 2019. № 1. C. 52–55. DOI: 10.18565/urology.2019.1.52-55

[39] Martov AG, Merinov DS, Kornienko SI, et al. Posleoperacionnye urologicheskie oslozhnenija transuretral’nyh jelektrohirurgicheskih vmeshatel’stv na predstatel’noj zheleze po povodu adenomy. Urologiia. 2006;(2):25–31. (In Russ.)

[40] Мартов А.Г., Меринов Д.С., Корниенко С.И., и др. Послеоперационные урологические осложнения трансуретральных электрохирургических вмешательств на предстательной железе по поводу аденомы // Урология. 2006. № 2. С. 25–31.

[41] Al-Shukri SK, Gorbachev AG, Borovets SY, et al. Lechenie bol’nyh adenomoj predstatel’noj zhelezy prostatilenom. Urologiia. 2006;(6):22–25. (In Russ.)

[42] Аль-Шукри С.X., Горбачев А.Г., Боровец С.Ю., и др. Лечение больных аденомой предстательной железы простатиленом // Урология. 2006. № 6. С. 22–25.

[43] Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA, Barannikov II. Chronobiological status of patients with chronic prostatitis and prostate adenoma. Sistemnyj analiz i upravlenie v biomedicinskih sistemah. 2017;16(3):513–516. (In Russ.)

[44] Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А., Баранников И.И. Хронобиологический статус больных хроническим простатитом на фоне аденомы предстательной железы // Системный анализ и управление в биомедицинских системах. 2017. Т. 16, № 3. С. 513–516.

[45] Lanina VA, Himicheva MN, Kuz’menko VV, et al. Hronobiologicheskie osobennosti bol’nyh s hronicheskim prostatitom pri adenome prostaty. Tendencii razvitija nauki i obrazovanija. 2020;66(1):111–114. (In Russ.)

[46] Ланина В.А., Химичева М.Н., Кузьменко В.В., и др. Хронобиологические особенности больных с хроническим простатитом при аденоме простаты // Тенденции развития науки и образования. 2020. Т. 66, № 1. С. 111–114.

[47] Hanina EA, Zujkova AA, Pashkov AN. Individual’nyj hronoritm v kontekste korrekcii narushenij adaptacii pri patologii vnutrennih organov. Bukovinian Medical Herald. 2009;13(24):259–260. (In Russ.)

[48] Ханина Е.А., Зуйкова А.А., Пашков А.Н. Индивидуальный хроноритм в контексте коррекции нарушений адаптации при патологии внутренних органов // Буковинский медицинский вестник. 2009. Т. 13, № 24. С. 259–260.

[49] Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA. Chronobiological approach to the treatment of chronic recurrent bacterial cystite. Urologiia. 2017;(2):60–65. (In Russ.) DOI: 10.18565/urol.2017.2.60-65

[50] Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Хронобиологический подход к терапии хронического рецидивирующего бактериального цистита в стадии обострения // Урология. 2017. № 2. C. 60–65. DOI: 10.18565/urol.2017.2.60-65

[51] Popkov VM, Kirichuk VF, Loyko VS, et al. Experience of terahertz therapy in benign prostatic hyperplasia combined with chronic abacterial prostatitis. Saratov Journal of Medical Scientific Research. 2014;10(4):649–654. (In Russ.)

[52] Попков В.М., Киричук В.Ф., Лойко В.С., и др. Опыт применения терагерцевой терапии у больных аденомой простаты в сочетании с хроническим абактериальным простатитом // Саратовский научно-медицинский журнал. 2014. Т. 10, № 4. С. 649–654.

[53] Vaupel P, Kelleher DK. Blood flow and oxygenation status of prostate cancers. Adv Exp Med Biol. 2013;765:299–305. DOI: 10.1007/978-1-4614-4989-8_42

[54] Vaupel P., Kelleher D.K. Blood flow and oxygenation status of prostate cancers // Adv Exp Med Biol. 2013. Vol. 765. P. 299–305. DOI: 10.1007/978-1-4614-4989-8_42

[55] Savushkin MS, Belova IB. The transrectal dopplerography in diagnostics of diseases of a prostate. Bulletin of Pirogov National Medical and Surgical Center. 2013;8(2):83–86. (In Russ.)

[56] Савушкин М.С., Белова И.Б. Трансректальная допплерография в диагностике заболеваний простаты // Вестник Национального медико-хирургического Центра им. Н.И. Пирогова. 2013. Т. 8, № 2. С. 83–86.

[57] Krupin VN, Krupin AV, Nashivochnikova NA. Evaluation of blood flow in prostate in patients with chronic bacterial prostatitis. Urologicheskie vedomosti. 2017;7(3):38–43. (In Russ.) DOI: 10.17816/uroved7338-43

[58] Крупин В.Н., Крупин А.В., Нашивочникова Н.А. Оценка кровотока в предстательной железе у больных хроническим бактериальным простатитом // Урологические ведомости. 2017. Т. 7, № 3. C. 38–43. DOI: 10.17816/uroved7338–43

[59] Al-Shukri SK, Gorbachev AG, Borovets SY. Pathogenesis and prophylaxis of chronic prostatitis (clinical and experimental study). Urologicheskie vedomosti. 2012;2(2):15–19. (In Russ.) DOI: 10.17816/uroved2215-19

[60] Аль-Шукри С.Х., Горбачев А.Г., Боровец С.Ю., и др. К патогенезу и профилактике хронического простатита (клинико-экспериментальное исследование) // Урологические ведомости. 2012. Т. 2, № 2. C. 15–19. DOI: 10.17816/uroved2215-19

[61] El Basri A, Petrolekas A, Cariou G, et al. Clinical significance of routine urinary bacterial culture after transurethral surgery: results of a prospective multicenter study. Urology. 2012;79(3):564–569. DOI: 10.1016/j.urology.2011.11.018

[62] El Basri A., Petrolekas A., Cariou G., et al. Clinical significance of routine urinary bacterial culture after transurethral surgery: results of a prospective multicenter study // Urology. 2012. Vol. 79, No. 3. P. 564–569. DOI: 10.1016/j.urology.2011.11.018

[63] Choong S, Whitfield H. Biofilms and their role in infections in urology. BJU Int. 2000;86(8):935–941. DOI: 10.1046/j.1464–410x.2000.00949.x

[64] Choong S., Whitfield H. Biofilms and their role in infections in urology // BJU Int. 2000. Vol. 86, No. 8. P. 935–941. DOI: 10.1046/j.1464-410x.2000.00949.x

RIGHTS & PERMISSIONS

Eco-Vector